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Abstract
Background: Many devices are in use to prevent pressure ulcers, but from most little is known about their effects
and costs. One such preventive device is the Australian Medical Sheepskin that has been proven effective in three
randomized trials. In this study the costs and savings from the use of the Australian Medical Sheepskin were
investigated from the perspective of a nursing home.
Methods: An economic model was developed in which monetary costs and monetary savings in respect of the
sheepskin were balanced against each other. The model was applied to a fictional (Dutch) nursing home with 100
beds for rehabilitation patients and a time horizon of one year. Input variables for the model consisted of
investment costs for using the sheepskin (purchase and laundry), and savings through the prevented cases of
pressure ulcers. The input values for the investment costs and for the effectiveness were empirically based on a
trial with newly admitted rehabilitation patients from eight nursing homes. The input values for the costs of
pressure ulcer treatment were estimated by means of four different approaches.
Results: Investment costs for using the Australian Medical Sheepskin were larger than the monetary savings
obtained by preventing pressure ulcers. Use of the Australian Medical Sheepskin involves an additional cost of
approximately €2 per patient per day. Preventing one case of a sacral pressure ulcer by means of the Australian
Medical Sheepskin involves an investment of €2,974 when the sheepskin is given to all patients. When the
sheepskin is selectively used for more critical patients only, the investment to prevent one case of sacral pressure
ulcers decreases to €2,479 (pressure ulcer risk patients) or €1,847 (ADL-severely impaired patients). The factors with
the strongest influence on the balance are the frequency of changing the sheepskin and the costs of washing
related to this. The economic model was hampered by considerable uncertainty in the estimations of the costs of
pressure ulcer treatment.
Conclusions: From a nursing home perspective, the investment costs for use of the Australian Medical Sheepskin
in newly admitted rehabilitation patients are larger than the monetary savings obtained by preventing pressure
ulcers.
Background
Pressure ulcers are a highly prevalent problem, espe-
cially in nursing home patients [1,2]. They have a large
impact on quality of life [3,4] and high costs are
involved in the treatment [5-7].
However, pressure ulcers can to a large extent be pre-
vented by adequate care. There are many devices to
help in the prevention of pressure ulcers [8], but
for many there is lack of knowledge about the (cost)-
effectiveness [9,10]. However, governments increasingly
urge guideline developers to base their recommenda-
tions regarding the use of certain devices not only on
effectiveness data but also on economic considerations. * Correspondence: p.mistiaen@nivel.nl
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tralian Medical Sheepskin (AMS), that has been proven
effective in two RCTs in hospital patients [11,12] and in
a recent RCT in a nursing home setting [13,14].
The Australian Medical Sheepskin is a real genuine
sheepskin, coming from the Australian Merino sheep.
The sheepskin has a wool pile length of 30 mm, and a
high density of wool piles, and reduces pressure and
friction making it a possible good intervention for the
prevention of pressure ulcers. The sheepskin is tanned
and processed in such a way that it has an increased
resistance to urine and can withstand up to 100 washes
at 80°C to achieve high-level thermal disinfection, with-
out losing its moisture absorbing and pressure relieving
properties.
Although there are some studies [5,7,15-18] on the
cost-effectiveness of preventative measures and appli-
ances for pressure ulcers, no study known to us presents
economical data for this Australian Medical Sheepskin.
In conjunction with the nursing home trial [13,14]
economic data were gathered and will be presented in
this article. The following research questions will be
addressed:
1. What are the (yearly) investment costs for using
the Australian Medical Sheepskin?
2. What are the (yearly) savings from use of the Aus-
tralian Medical Sheepskin by preventing cases of
pressure ulcers?
3. What is the balance between costs and savings
from the use of the Australian Medical Sheepskin
and what factors are most influential in this regard?
These questions will be answered through a cost-
effectiveness analysis performed from the perspective of
a fictional (Dutch) nursing home.
Methods
The design for this study is a cost-effectiveness analysis,
done in a model from the perspective of a fictional
Dutch nursing home and with a time horizon of 1 year.
The pricing year was 2008 and actual prizes were
applied so discounting was not needed, except for one
estimate derived from a literature source. The currency
used is Euro (€).
The research questions can be reworded as an equa-
tion: (Investment costs AMS (=purchase + laundry)) -
(SAVINGS (=effectiveness AMS * costs of pressure ulcer
treatment)) = BALANCE. Investment costs consist of
costs related to purchase the AMS and costs related to
using and washing the AMS. The savings are the num-
ber of patients that are prevented from a pressure ulcer
by use of the AMS multiplied by the costs of treating a
pressure ulcer. The equation was applied in a model for
a fictional Dutch nursing home; the input values for the
equation were based as much as possible on the empiri-
cal data from the above-mentioned RCT in eight Dutch
nursing homes, and where needed, were supplemented
through other sources. This trial formed the main
source of data for the analysis of investments costs and
the effectiveness. In the trial 588 newly admitted
patients, mainly with a rehabilitation purpose, were ran-
domized to either the control group that received usual
care only or to the intervention group that received
usual care and an Australian Medical Sheepskin. All
patients were monitored for the development of sacral
pressure ulcers from admission until 30 days thereafter.
The experimental group received usual care plus an
Australian Medical Sheepskin as a layer on the mattress
within ultimately 48 hours after admission; the control
group received usual care only. Usual care was all care
that nursing wards normally applied for pressure ulcer
prevention without any further standardization for this
study. The incidence of sacral pressure ulcers grade 1 or
higher was significantly lower in the experimental group
than in the control group (8.9% versus 14.7%). This
means a relative risk of 0.61 (95% CI: 0.37 to 0.96).
These results are in line with the results of two earlier
trials [11,12] on the Australian Medical Sheepskin in
hospital patients.
Because only a few patients in that Dutch trial devel-
oped a sacral pressure ulcer, limiting the base for
recording therapy costs, additional sources were used to
estimate the pressure ulcer treatment costs.
All data obtained were then converted to input values
for a fictional model nursing home anno 2008 for which
yearly investment costs and savings were balanced.
General model characteristics
The perspective for the analysis is the nursing home,
meaning only expenses from and savings to the nursing
home budget are taken into account. Only direct costs
were counted. Assumed characteristics for the fictional
nursing home of the model are that it has 100 beds for
patients admitted for a primarily physical impairment,
the occupancy rate is 100%, and it has 468 new admis-
sions per year (based on a mean length of stay of 78
days as found in the Dutch trial [13]). The model was
confined to direct monetary investments and monetary
savings by the AMS use only. The time frame is one
year.
Furthermore, the model is limited to savings from
treatment of pressure ulcers in the sacral region only
and solely grade 1 and 2. This choice is based on the
fact that the primary outcome of the aforementioned
trial was the incidence of sacral pressure ulcers and
because sacral pressure ulcers are the most common
form of pressure ulcers in nursing home patients. The
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g r a d e1a n d2u l c e r sf o r mt h el a r g em a j o r i t y( a b o u t
80%) of all sacral pressure ulcers in nursing homes
[19-21] and there is no evidence yet that the AMS is
also capable of preventing grade 3 or 4 pressure ulcers
or of preventing pressure ulcers grade 1 or 2 from dete-
riorating to more severe grades. Furthermore in the
model a ratio of 70% grade 1 versus 30% grade 2 pres-
sure ulcers was used, as found in the Dutch trial.
In the model a base case was developed in which all
variables were set to the most plausible values, based
primarily on the trial and following discussion by the
research project group that weighted additional sources.
Thereafter one-way sensitivity analyses with a low and a
high value for each of the input variables were per-
formed to calculate the relative impact of the model
components. In addition, the values for the sensitivity
analyses were chosen after discussion in the research
project group, based primarily on practical considera-
tions rather than on mathematical grounds (e.g. the
values for frequency of changing the AMS was varied
between every 3 days to daily and every 5 days, instead
of a percentage increase or decrease).
Since the monetary investments and the effectiveness
depend on the number and kind of patients using the
AMS, the model was calculated for 3 scenarios: AMS
use for all patients, AMS use only for patients with a
risk on pressure ulcers at admission (score ≤20 on the
Braden-scale [22]) and AMS use only for patients that
are severely ADL-impaired at admission (score <10 on
the Barthel-index [23]). For the model the number of
patients at risk for pressureu l c e r s( 7 0 % )a n dt h en u m -
ber of patients that are severely ADL-impaired (45%)
were derived from the Dutch trial [13].
Prices for products and devices used in the pressure
ulcer treatment were based on the (Dutch) websites
http://www.huidziekten.nl, or http://www.medicijnkos-
ten.nl (these sites were visited during summer 2009). If
no prices could be found at these sites data were used
from a price list from a Dutch nursing home that parti-
cipated in the trial. All prices were calculated on the
basis of daily costs, accounting for the frequency of
dressing change. Costs relating to salaries for personnel
were based on actual gross mid-salary scales 2008
http://www.actiz.nl/cms/streambin.aspx?reques-
tid=3517B57E-F9F5-4D8D-A682-1E92DAABFA50[24]
for Dutch nursing homes (a total of 1872 working hours
per year was assumed and extra payments for irregular
shifts were not counted). This resulted in €0.22 per min-
ute for a nursing assistant, €0.30 per minute for a nurse
practitioner/wound care nurse, €0.34 per minute for a
dietician/paramedic and €0 . 5 4p e rm i n u t ef o ran u r s i n g
home physician. Time for a consultation of, for example,
a nurse practitioner, dietician or other specialist was set
at 15 minutes. And it was assumed that this consulta-
tion was valid for ten days; therefore each consultation
time was divided by ten to arrive to a price per day.
Costs for hiring/purchasing special anti-pressure ulcers
mattresses were not counted, since it was not clear to
what extent these mattresses are only used for therapy,
or also for prevention or to what extent they are stan-
dard mattresses. Costs relating to nursing time for repo-
sitioning were counted as treatment costs, since the
Dutch National Prevalence Surveys of Care Problems
clearly show that repositioning is used far more in
patients with than in patients without pressure ulcers
(38% versus 13%) [19-21].
To estimate the mean duration of a sacral pressure
ulcer literature sources [19-21,25-28] were used. How-
ever, no clear data were found on how long pressure
ulcers in general persist; data in the literature varied
from less than 2 weeks to 3 years. After discussion in
the research project group a period of 16 days for a
grade 1 and of 40 days for a grade 2 were set as the
most plausible values for the duration.
The estimated time for repositioning was set at 10
minutes per turn, also based on data in the literature
[7,29-34] that varied between 2 and 12.5 minutes per
turn.
All calculations were performed in an Excel-
spreadsheet.
Model input values for investment costs
The investment costs were calculated with the following
variables: purchase price of an AMS, the price of wash-
ing a single AMS, the durability/life span of an AMS,
the required time for bringing the AMS to the laundry
and back to the ward, and the frequency with which an
AMS in bed is changed. Table 1 shows the input values
for these variables. The main source was the Dutch trial,
with supplementary data from other sources.
Model input values for the savings from AMS use
The savings from the use of the AMS depend on the
number of patients that are prevented from getting a
sacral pressure ulcer grade 1 or 2 (effectiveness) multi-
plied by the costs for treatment of a sacral pressure
ulcer grade 1 or 2, taking into account the ratio between
grade 1 and 2 pressure ulcers.
Input data about the effectiveness of the AMS were
based on the aforementioned Dutch RCT [13]. Since
patients in this trial were followed from admission until
30 days later or until death or discharge, it means that
the effectiveness ratio has a time frame of 30 days and it
is assumed that no new pressure ulcers develop after
this initial 30-day period. The incidence of sacral pres-
sure ulcers in that trial was 14.7% in the control group
versus 8.9% in the intervention group when analysed for
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patients with a risk on pressure ulcers and 24.8% versus
15.2% in the severely ADL-impaired patients. The differ-
e n c e si ni n c i d e n c e sf r o mt h i st r i a lw e r er o u n d e dt ob e
used as input values for the effectiveness in the model
(Table 2).
For the scenario using the AMS for all patients, an
incidence difference of 6 was chosen as the base case
value. Or in other words, use of the AMS for all
admitted patients in the model nursing home with 468
admissions per year prevents 28 cases of sacral pressure
ulcers. In the scenario where the AMS is used only for
the 70% of patients with a pressure ulcer risk and a risk
difference of 7, it prevents 23 cases of sacral pressure
ulcers yearly. And in the scenario where the AMS is
used only for the 45% of ADL-severely impaired patients
and a risk difference of 9, the AMS prevents 19 cases of
sacral pressure ulcers per year.
The costs of treatment of sacral pressure ulcer grade 1
or 2 were estimated on the basis of a combination of
four approaches: the guideline approach, the National
Prevalence Survey of Care Problems (NPSCP) approach,
the empirical approach and the literature approach.
The first approach is based on the care described as
appropriate in the Dutch national guideline on pressure
ulcers [35]. The recommended actions in that guideline
were seen as units and volume indicators and turned
into cost-data (see Table 3). This approach resulted in
estimated treatment cost of €14.16 per ulcer per day.
Secondly, data from The Dutch National Prevalence
Survey of Care Problems were used http://www.lpz-um.
eu[19-21]. In these surveys data about the prevalence,
the location and the applied treatment of pressure ulcers
are gathered yearly on a given day in all patients of par-
ticipating health care institutions. We used data of three
consecutive years (2006-2007-2008) on nursing home
patients that were registered as having a sacral pressure
ulcer (N = 2,772 patients from 157 different nursing
homes, consisting of 1,517 patients with a grade 1, 820
grade 2, 288 grade 3 and 147 with a grade 4 sacral pres-
sure ulcer). For these patients pressure ulcer treatment
as recorded was converted into cost data. The treatment
components consisted of repositioning, skin protection,
wound care products, consultation with a dietician and
other nursing activities. Because only categories of
wound care products were recorded instead of a specific
brand and size of product, the price for the cheapest
wound care product from that category was used in the
cost calculations. In case a recorded product is usually
in situ for a number of days, the product price was
divided by the usual number of days. For each patient
we checked if such an activity or product was recorded
for that day and if so, a price label was added. With
regard to repositioning, these data mentioned only if the
patients received repositioning but not the frequency or
by whom the repositioning was performed. Therefore
we assumed, based on the experiences of those members
of the research group who were working in a nursing
Table 1 Input values for investment costs for using the AMS
Input variables Unit Sources Input values
Trial Other Low Base High
Purchase price AMS € 85 15 quotes other AMS-suppliers: 75 85 95
range 60-372;
median 87
Price single washing € 6-6.6 6 quotes other laundries: 4 6 8
range 0.7-15;
median 2.5
Frequency change AMS days 4.8 Research protocol [37]: 3 1 3 5
Length resupply days 3 - 1 3 5
Durability AMS cycles - Research protocol [37]: 50 30 50 70
Developer [40,41]: 60-100
Needed stock number 200 - 200 200 200
Needed extra stock for calamities % 30 - 10 30 50
Table 2 Input values for the effectiveness of the AMS
Scenario Input values for the difference in pressure ulcer incidence (%)
Low Base High
All patients 5 6 7
Patients at risk for pressure ulcers 6 7 8
Severely ADL-impaired patients 8 9 10
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formed by a nursing assistant. Subsequently, a mean
price for the patients with a pressure ulcer was calcu-
lated, resulting in €5.2 (sd = 6.37; min-max: 0-20.1) per
d a yf o rag r a d e1a n d€6.3 (sd = 6.74; min-max: 0-19.6)
for a grade 2 ulcer.
The third approach consisted of a convenience sample
of nineteen nursing home patients from six different
nursing homes that developed a sacral pressure ulcer. In
these patients a diary was kept in which all therapy and
the personnel involved in the treatment were prospec-
tively charted. A wound-care nurse or pressure-ulcer
nurse specialist filled out this diary every day from the
onset of a sacral pressure ulcer during the whole period
that it existed (or until discharge or death). She noted
daily the grade of the ulcer, the wound care products
used, special pressure relieving devices, kind and time of
specialists that were consulted, diagnostic procedures
and extra time for nursing personnel that was devoted
to pressure ulcer care. This approach resulted in a mean
treatment cost of €12.6 (sd = 4.4; min-max 3.7-20.6) per
day for a grade 1 and €13.2 (sd = 5.1; min-max 3.5-18.5)
for a grade 2 sacral pressure ulcer.
Finally, we made use of the articles related to the
Dutch situation that were included in a recent systema-
tic review [36] about treatment costs for sacral pressure
ulcers in nursing home patients. However, the review
included only one study relating to the Dutch situation.
This Dutch cost-of illness study [5] gave a mean of €25
per patient per day for a grade 1 and €54 for a grade 2
pressure ulcer (values were discounted to year 2008).
An overview of the estimates found in the four
approaches is shown in Table 4. Based on these different
sources and after discussion in the research project
group it was decided to use €1 5 / d a yf o rag r a d e1a n d
€17/day for a grade 2 pressure ulcer as input values for
the base case in the model and +/-5€ for the sensitivity
analyses. Expressed as costs per pressure ulcer period
a n dw i t ha na s s u m e dd u r a t i o no f1 6d a y sf o rag r a d e1
and 40 days for a grade 2 ulcer, this results in €240 and
€680 respectively.
Ethical considerations
For the randomized trial that was part of this economic
analysis, patients were informed by the admitting nurse
verbally and in written format about the research project
before they were asked to participate and before they
signed the informed consent form. At all times patients
were free to withdraw from the study without having to
give a reason for doing so.
The study protocol was approved by the certified
Medical Ethics Review Board of the University Medical
Centre of Utrecht (protocol number 06/287), on behalf
of all the participating nursing homes.
The Board of Directors of each participating nursing
home signed a form in which they stated they have read
and understood the research protocol and that there
were no obstacles at all to conducting the research in
their organizations.
The scientific merits of the study protocol have been
reviewed in the consecutive phases of the research fund-
ing process by independent reviewers of the funding
organization ZonMw, the Netherlands Organization for
Health Research and Development (http://www.zonmw.
nl/en; ZonMw grant number 945-07-513).
Besides this, the research protocol, and more specifi-
cally the washing procedure of the sheepskins, has also
been evaluated by the Dutch Working Party on Infec-
tion Prevention http://www.wip.nl/UK/ and approved as
safe.
Table 3 Cost of treating pressure ulcers grade 1 or 2 per day, based on pressure ulcer guideline [35]
Action/Unit Recommend volume Price per unit Formula Costs per day
(€)
Repositioning every 4 hours during a 24 hour period
(by a care assistant)
6 × 10 minutes =
60 minutes
€0.22 per
minute
60*0.22 13.20
Anti-pressure ulcer mattress Not counted Not counted
Informing patient Not counted Not counted
Assessing nutritional status and giving adequate
nutrition
Single consultation with a dietician €0.34 per
minute
(15*0.34)/
10
0.51
Assessing and treating pain
&
Assessing psychosocial situation
Single consultation with a nurse
practitioner
€0.30 per
minute
(15*0.30)/
10
0.45
TOTAL 14.16
Table 4 Input values for mean cost of pressure ulcer
treatment per day per grade (€)
Sources Input values
guideline Npscp empirical literature Low Base High
Grade 1 14.2 5.2 12.6 25.0 10 15 20
Grade 2 14.2 6.3 13.2 54.0 12 17 22
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ister as ISRCTN17553857 and has been published ear-
lier [37].
The patient data from The Dutch National Prevalence
Survey of Care Problems http://www.lpz-um.eu were
given to us without identifying information of both
patients and institutions.
Results
What are the investment costs for using the AMS?
When the AMS is used for all newly admitted patients,
it requires a yearly investment of nearly €94,000. When
the AMS is used for selected groups only, the total
investments costs are €65,578 for use solely in patients
that are admitted with a risk on pressure ulcers and
€42,158 for use in severely ADL- impaired patients only
(Table 5). The washing accounts for almost 80% of the
total costs.
What are the savings from use of the AMS?
Savings are calculated from the number of patients in
which sacral pressure ulcers are prevented, multiplied
by the costs of sacral pressure ulcer treatment (Table 6).
The total savings per year for the model nursing home
are 10,416€, when the AMS is provided to all patients. If
the model is changed to a scenario in which the AMS is
only given to patients with a risk on pressure ulcers, the
annual savings are 8,556€. In the scenario where the
AMS is only given to severely ADL-impaired patients
the savings are 7,068€ per year from prevented sacral
pressure ulcer cases.
What is the balance between the costs of and savings
from using the AMS?
In the scenario where the AMS is used for all patients a
yearly investment of €93,683 was needed and the savings
were estimated at €10,416. This means an extra invest-
ment of €83,267 per year is required for the model nur-
sing home of 100 beds and 468 new admissions
annually. In other words, use of the AMS requires an
additional investment of €178 per new patient. Trans-
lated into a price per patient per day, it means an extra
investment of €2.28. This means that the net investment
needed to prevent one case of sacral pressure ulcer by
means of the AMS amounts €2,974 in this scenario.
When the AMS is used more selectively, i.e. only for
patients with a risk on pressure ulcers or only for
severely ADL-impaired patients, then the total invest-
ment become smaller due to fewer patients, while the
savings are relatively higher due to better effectiveness
figures. In these scenarios the net investment drops to
€2,479 and €1,847 respectively per case prevented for
use in pressure ulcers-risk patients and severely ADL-
impaired patients. Expressed as an additional cost per
day per patient who gets an AMS, it means €2.23 and
€2.14. Table 7 shows the figures for the 3 scenarios. In
all scenarios the investment costs for use of the AMS
are larger than the savings the AMS creates.
Sensitivity Analyses
Table 8 shows in decreasing order the relative impact of
the various input variables as found by sensitivity ana-
lyses on the final balance, expressed as additional costs
per day for use of the AMS in all patients. These sensi-
tivity analyses show that the extra investment per day is
largely influenced by the frequency of changing the
AMS (due to the associated washing costs). Even if the
low and high input values are altered to a changing fre-
quency of every 4 days and every 2 days this factor
remains the most influential. Second most influential
factor is the cost of washing. Other factors such as the
initial purchase price, the durability of the AMS, the
effectiveness of the AMS or the costs of treating a pres-
sure ulcer have much less impact on the balance. Even
if the treatment costs per day are doubled, the balance
keeps showing an extra investment of €2. In the scenar-
ios where the AMS is selectively used, the same factors
are the most influential in the sensitivity analyses.
Discussion
This economic impact analysis of the AMS has demon-
strated that the investment costs for using the AMS are
larger than the savings obtained by avoided pressure
ulcer treatment. The extra investment is approximately
€2.28 per patient per day when used for all patients,
decreasing to €2.23 when used only for pressure ulcers-
Table 5 Annual investment costs for the AMS
Unit Scenario
All
patients
Only patients with pressure
ulcer risk
Only severely ADL-impaired
patients
Initial investment for purchase taking into account the durability
of the AMS
€ 20,683 14,478 9,308
Costs for washing € 73,000 51,100 32,850
TOTAL costs per year € 93,683 65,578 42,158
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ADL-impaired patients. Expressed in another way, the
costs in the respective scenarios are €2,974 to €2,479
and €1,847 to prevent one case of sacral pressure ulcer
by means of the AMS. In practice these balance figures
may vary, due to the large number of variables that
influence them. Furthermore, there is much uncertainty
in the model. The uncertainty pertains to all compo-
nents of the model but most to the costs of treatment
for pressure ulcers and less to the investment costs or
the effectiveness rate. In particular, the costs per pres-
sure ulcer period are surrounded by considerable uncer-
tainty since these were based on a calculation of an
uncertain price per day multiplied by an uncertain dura-
tion of a pressure ulcer.
It must, however, be stressed that conservative
approaches have been used, meaning that input values
for the model were never chosen in a way that clearly
favoured the AMS. For instance, the costs of treatment
for a pressure ulcer are more likely to be an underesti-
mate. This is because not all possible treatment costs
were counted, such as costs for special mattresses or the
time involved for nurse assistants to go to and from a
patient when repositioning; or the cheapest product of a
category was chosen if it was not clear which product
was used in reality and only direct costs were counted.
However, although the treatment costs may be an
underestimate, the sensitivity analyses show that even a
doubling of these treatment costs doesn’tr e s u l ti na
complete different balance.
This study has several limitations that have to be kept
in mind when interpreting the results. First of all, the
results presented are based on a model, which is by defi-
nition only a limited approximation of a real world
situation. Furthermore the study is limited by the fact
that we did not have data about qualitative savings for
patients related to not having a sacral pressure ulcer. In
this way QALY’s (quality-adjusted life years) could not
be computed and this hindered us in performing a com-
plete cost-effectiveness analysis and in comparing our
figures to accepted cost-effectiveness thresholds.
Moreover, a specific population with a majority of
rehabilitation patients was used in the model. These
rehabilitation patients have a shorter length of stay than
the more chronic patients that usually form a large pro-
portion of a normal real world nursing home. Besides,
most rehabilitation patients get better, while the more
chronic patients have a deteriorating course with an
increasing risk on pressure ulcers. It may be the case
that the balance would be more in favour of the AMS if
it were used in such chronic patients.
The model also assumed that no pressure ulcers develop
after the first 30 days following admission, and the AMS
has no additional effect after this period. This is not cer-
tain and therefore the balance could in reality be more in
favour of the AMS if the preventive effect lasts longer.
Sensitivity analyses demonstrated that the frequency of
changing the AMS and the cost of washing are the most
influencing factors. This means that the nursing home
itself can influence the balance through negotiations
with laundries about the price and through a well
thought-out system of changing the AMS. It also means
that there is a challenge for the industry to find laundry
processes that are less expensive, in order to make the
AMS more attractive.
From an economic point of view it would seem most
logical to give the AMS only to a selection of patients,
e.g. only to severely ADL-impaired patients, since the
initial investment is lower due to the smaller number of
patients, and the effectiveness of the AMS is relatively
Table 6 Annual savings from using the AMS
Scenario N prevented from sacral pressure ulcer
(70/30% grade 1/2)
Cost per period Savings (€) per year
All patients 28 (28*70%) * 240
(28*30%) * 680
10,416
Only patients pressure ulcer risk 23 (23*70%) * 240
(23*30%) * 680
8,556
Only severely ADL-impaired patients 19 (19*70%) * 240
(19*30%) * 680
7,068
Table 7 Balance between investments for and savings from using the AMS
Scenario Investment costs
(€) per year
Savings (€)
per year
Balance
(€)
N prevented from
sacral pressure ulcer
Costs to prevent 1 case of
sacral pressure ulcer
Additional costs per
day per patient
ALL patients 93,683 10,416 83,267 28 2,974 2.28
Only patients with
pressure ulcer risk
65,578 8,556 57,022 23 2,479 2.23
Only severely ADL-
impaired patients
42,158 7,068 35,090 19 1,847 2.14
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between investments and savings. However, being selec-
tive also implies that a screening instrument is needed
at admission, with all energy needed for that and with
all possible mistakes/misclassifications that can occur.
Therefore, from a practical point of view, it may be
much easier to give the AMS to all patients initially and
to reconsider the need for it later on.
In the debate whether to use the AMS or not, an eva-
luation of the extra investment is required. Is the extra
2.3€ per day to be valued as small or large? Expressed
as percentage of the total amount of money a Dutch
nursing home receives from the health care insurance
for 1 day of care for a rehabilitation patient (ZZP-9 =
€189.14; http://www.nza.nl[38]) the extra investment for
using the AMS is about 1.2%. And who is at stake when
the evaluations and decisions are made? Is it the man-
ager, the physician, the specialized nurse, the nurse
assistant or the patient? Furthermore, in that debate it
has to be considered that the presented model was con-
fined to monetary savings only. Qualitative savings such
as gains in quality of life for patients that were pre-
vented from pressure ulcers, comfort of the AMS for
patients or practicality for nurses were not taken into
account in this economic model. Although a recent
study [39] gives figures on health utilities and the
impact of pressure ulcers in long term care residents,
these utilities were grouped into a utility for either a
group with no or with grade 1 pressure ulcer and a
group with grade 2, 3 and 4 together, making these fig-
ures not applicable to this study.
It is also not known yet how the additional investment
for the AMS compares to extra investments for other
alternative appliances/methods to prevent sacral pres-
sure ulcers.
Accordingly, all these issues have to be taken into
account before judging whether the AMS is good value
for money or not.
At least it has now been proven in three RCTs [11-14]
that the AMS is an effective aid for the prevention of
pressure ulcers, and this paper provides an estimation of
the required extra investments for use in a specific nur-
sing home population. This is much more than can be
said about other preventive aids for pressure ulcers.
Finally, this economic analysis was performed from
the perspective of a Dutch nursing home. This means
that these results can not be extrapolated in a straight-
forward way to other health care settings or to other
countries. Extrapolating this model to another country
would require data of that other country about salaries
and costs of wound products, but it is unlikely that a
completely different picture would arise. If the model
were to be developed for a hospital setting, there is a
chance that the balance would be more in favour of the
AMS, because the costs of pressure ulcer treatment in a
hospital setting will probably be larger due to extra
length of stay for pressure ulcer patients or to higher
salaries from the hospital personnel involved. This was
demonstrated in a recent study [7], where treating a
pressure ulcer grade 1 and 2 in a Dutch hospital setting
involved a cost of respectively more than 30 or 50€ per
day, which is much higher than the estimates of 15 and
17€ for a Dutch nursing home we applied in our analy-
sis. Using another perspective than the nursing home,
e.g. a societal perspective or a patient perspective, would
also result in other outcomes.
Table 8 Sensitivity analyses for the additional costs per patient per day
Factor Input values* Additional cost per
day
Difference between low-high, as % of base value
Low Base High Low Base High
Frequency of changing 5 3 1 1.25 2.28 7.41 270
Cost of washing 4 6 8 1.61 2.28 2.95 59
Durability of AMS 70 50 30 2.12 2.28 2.66 24
Purchase price of AMS 75 85 95 2.21 2.28 2.35 6
Price per day of treating pressure ulcer grade 1 20 15 10 2.24 2.28 2.32 4
Price per day of treating pressure ulcer grade 2 22 17 12 2.23 2.28 2.33 4
Duration in days pressure ulcer grade 1 22 16 10 2.23 2.28 2.33 4
Duration in days pressure ulcer grade 2 50 40 30 2.24 2.28 2.32 4
Effectiveness of AMS 7 6 5 2.23 2.28 2.33 4
Ratio between grade 1 and 2 pressure ulcer 60/40 70/30 80/20 2.25 2.28 2.31 3
Length of stay 70 78 86 2.25 2.28 2.31 3
Extra stock 10 30 50 2.28 2.28 2.28 0
Length of wash/supply cycle 1 3 5 2.28 2.28 2.28 0
*The low input values are all these that influence the balance in the direction of favouring the AMS
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From this economic model study, it can be concluded
that from the perspective of a nursing home, the invest-
ment costs for use of the Australian Medical Sheepskin
in newly admitted rehabilitation patients are larger than
the monetary savings obtained by preventing pressure
ulcers.
Using the AMS involves an additional cost of
approximately €2 per day per patient. By far the
greatest influence on the balance between investment
and savings is the cost of washing the AMS. However
these conclusions are hampered by the considerable
uncertainty about the costs of pressure ulcer
treatment.
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